The IBS-C market of North America is evaluated to grow at a CAGR of 8.68% over the projected period, 2020-2028.  The important factors boosting the market growth are growing lifestyle–oriented diseases, severe gastrointestinal infection, rise in healthcare expenditure, increasing number of patients suffering from depression, and medical advancements.

NORTH AMERICA IBS-C DRUG MARKET FORECAST 2020-2028

North America Ibs-c Drug Market by Drug Type (Overview (Lubiprostone, Linaclotide, Stimulant Laxatives, Osmotic Laxatives, Others (Psyllium)), Pipeline Drug Analysis: Plecanatide)  by Prescription Type (Prescribed Drugs, Over the Counter Drugs) by Geography

Request free sample

The IBS-C market of North America is evaluated to grow at a CAGR of 8.68% over the projected period, 2020-2028.  The important factors boosting the market growth are growing lifestyle–oriented diseases, severe gastrointestinal infection, rise in healthcare expenditure, increasing number of patients suffering from depression, and medical advancements.

In order to understand the North American IBS-C drug market growth, the region is segmented into countries such as the US and Canada. The US is the most developed country in terms of medical treatments and the latest technologies. The positive market growth prospects in the US region is attributed to the government initiatives dedicated to improving the healthcare segment of the society through the latest technological advancements and advanced medication treatments support Healthcare expenditure is highest in the US as compared to other nations and accounts for 17.7% of the country’s GDP. More than 80% of the people in the US are suffering from IBSD and IBS-C. IBS is found mostly in people above 19 years, facing bad lifestyles with stress and depression issues or socio-economic issues. The US is a profitable market for IBS treatment drugs as fewer options and treatment alternatives are available in the market, and the number of patients for IBS is high in the country. Some of the major drugs found in the US are Amitiza, Linzess, Eluxadoline, etc.

Catalent Pharma Solutions, headquartered in Somerset, Franklin, New Jersey, US, is a provider of drug delivery technology and development solutions for drugs, biologics, and consumer health products.

To request a free sample copy of this report, please complete the form below:

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

    1. RESEARCH SCOPE & METHODOLOGY
      • STUDY OBJECTIVES
      • SCOPE OF STUDY
      • METHODOLOGY
      • ASSUMPTIONS & LIMITATIONS
    2. EXECUTIVE SUMMARY
      • MARKET SIZE & ESTIMATES
      • MARKET OVERVIEW
    3. MARKET DYNAMICS
      • MARKET DEFINITION
      • KEY DRIVERS
        • MODERN DIETARY HABITS TAKING TOLL ON THE HEALTH
        • IBS CAN BE A HERITABILITY ISSUE
        • AVAILABILITY OF EFFECTIVE DRUGS IN THE MARKET
      • KEY RESTRAINTS
        • STRICT FDA REGULATIONS
        • UNAWARENESS AND IGNORANCE AMONG PEOPLE
    1. KEY ANALYTICS
      • KEY INVESTMENT INSIGHTS
      • PORTER’S FIVE FORCE ANALYSIS
        • BUYER POWER
        • SUPPLIER POWER
        • SUBSTITUTION
        • NEW ENTRANTS
        • INDUSTRY RIVALRY
      • OPPORTUNITY MATRIX
      • VENDOR LANDSCAPE
      • REGULATORY FRAMEWORK
    2. MARKET BY PRESCRIPTION TYPE
      • PRESCRIBED
        • BRANDED
        • GENERIC
      • OVER THE COUNTER
    3. MARKET BY DRUG TYPE
      • LUBIPROSTONE
      • LINACLOTIDE
      • STIMULANT LAXATIVES
        • BISACODYL
        • SENNA
      • OSMOTIC LAXATIVES
        • LACTULOSE
        • POLYETHYLENE GLYCOL
      • OTHER DRUG TYPES
    4. GEOGRAPHICAL ANALYSIS
      • NORTH AMERICA
        • UNITED STATES
        • CANADA
    1. COMPANY PROFILES
      • CATALENT PHARMACEUTICALS SOLUTIONS
      • ABBOTT LABORATORIES
      • NOVARTIS PHARMA AG
      • ASTELLAS PHARMACEUTICALS
      • ARDELYX, INC.
      • SYNTHETIC BIOLOGICS, INC.
      • TEVA PHARMACEUTICAL INDUSTRIES LIMITED
      • BAMA-GEVE, SLU
      • FERRING BV
      • IRONWOOD PHARMACEUTICALS, INC.
      • SALIX PHARMACEUTICALS LTD.
      • NORGINE B.V.
      • PROMETHEUS LABORATORIES, INC.
      • ALBIREO PHARMA, INC.
      • YUHAN CORP.
      • ASTRAZENECA PLC
      • THE MENARINI GROUP
      • ONO PHARMACEUTICAL CO. LTD.
      • ACTAVIS NORDIC A/S

     

    LIST OF TABLES

    TABLE 1: MARKET SNAPSHOT – IBS-C DRUG

    TABLE 2: REGULATORY FRAMEWORK

    TABLE 3: NORTH AMERICA IBS-C DRUG MARKET, BY PRESCRIPTION TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

    TABLE 4: NORTH AMERICA IBS-C DRUG MARKET, BY PRESCRIPTION TYPE, FORECAST YEARS, 2020-2028 (IN $ MILLION)

    TABLE 5: NORTH AMERICA IBS-C DRUG MARKET, BY PRESCRIBED, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

    TABLE 6: NORTH AMERICA IBS-C DRUG MARKET, BY PRESCRIBED, FORECAST YEARS, 2020-2028 (IN $ MILLION)

    TABLE 7: PRODUCT PROFILE (METHYL NALTREXONE BROMIDE)

    TABLE 8: NORTH AMERICA IBS-C DRUG MARKET, BY DRUG TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

    TABLE 9: NORTH AMERICA IBS-C DRUG MARKET, BY DRUG TYPE, FORECAST YEARS, 2020-2028 (IN $ MILLION)

    TABLE 10: PRODUCT PROFILE (LUBIPROSTONE)

    TABLE 11: PRODUCT PROFILE (LINACLOTIDE)

    TABLE 12: NORTH AMERICA IBS-C DRUG MARKET, BY STIMULANT LAXATIVES, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

    TABLE 13: NORTH AMERICA IBS-C DRUG MARKET, BY STIMULANT LAXATIVES, FORECAST YEARS, 2020-2028 (IN $ MILLION)

    TABLE 14: PRODUCT PROFILE (BISACODYL)

    TABLE 15: PRODUCT PROFILE (SENNA)

    TABLE 16: NORTH AMERICA IBS-C DRUG MARKET, BY OSMOTIC LAXATIVES, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

    TABLE 17: NORTH AMERICA IBS-C DRUG MARKET, BY OSMOTIC LAXATIVES, FORECAST YEARS, 2020-2028 (IN $ MILLION)

    TABLE 18: PRODUCT PROFILE (LACTULOSE)

    TABLE 19: PRODUCT PROFILE (POLYETHYLENE GLYCOL)

    TABLE 20: PRODUCT PROFILE (PSYLLIUM)

    TABLE 21: NORTH AMERICA IBS-C DRUG MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

    TABLE 22: NORTH AMERICA IBS-C DRUG MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)

     

    LIST OF FIGURES

    FIGURE 1: DRUGS PULLED OFF FROM THE MARKET

    FIGURE 2: KEY INVESTMENT INSIGHTS

    FIGURE 3: PORTER’S FIVE FORCE ANALYSIS

    FIGURE 4: OPPORTUNITY MATRIX

    FIGURE 5: VENDOR LANDSCAPE

    FIGURE 6: NORTH AMERICA IBS-C DRUG MARKET, GROWTH POTENTIAL, BY PRESCRIPTION TYPE, IN 2019

    FIGURE 7: NORTH AMERICA IBS-C DRUG MARKET, PRESCRIBED, 2020-2028 (IN $ MILLION)

    FIGURE 8: NORTH AMERICA IBS-C DRUG MARKET, BRANDED, 2020-2028 (IN $ MILLION)

    FIGURE 9: NORTH AMERICA IBS-C DRUG MARKET, GENERIC, 2020-2028 (IN $ MILLION)

    FIGURE 10: NORTH AMERICA IBS-C DRUG MARKET, OVER THE COUNTER, 2020-2028 (IN $ MILLION)

    FIGURE 11: NORTH AMERICA IBS-C DRUG MARKET, GROWTH POTENTIAL, BY DRUG TYPE, IN 2019

    FIGURE 12: NORTH AMERICA IBS-C DRUG MARKET, LUBIPROSTONE, 2020-2028 (IN $ MILLION)

    FIGURE 13: NORTH AMERICA IBS-C DRUG MARKET, LINACLOTIDE, 2020-2028 (IN $ MILLION)

    FIGURE 14: NORTH AMERICA IBS-C DRUG MARKET, STIMULANT LAXATIVES, 2020-2028 (IN $ MILLION)

    FIGURE 15: NORTH AMERICA IBS-C DRUG MARKET, BISACODYL, 2020-2028 (IN $ MILLION)

    FIGURE 16: NORTH AMERICA IBS-C DRUG MARKET, SENNA, 2020-2028 (IN $ MILLION)

    FIGURE 17: NORTH AMERICA IBS-C DRUG MARKET, OSMOTIC LAXATIVES, 2020-2028 (IN $ MILLION)

    FIGURE 18: NORTH AMERICA IBS-C DRUG MARKET, BISACODYL, 2020-2028 (IN $ MILLION)

    FIGURE 19: NORTH AMERICA IBS-C DRUG MARKET, POLYETHYLENE GLYCOL, 2020-2028 (IN $ MILLION)

    FIGURE 20: NORTH AMERICA IBS-C DRUG MARKET, OTHER DRUG TYPES, 2020 -2028 (IN $ MILLION)

    FIGURE 21: NORTH AMERICA IBS-C DRUG MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)

    FIGURE 22: UNITED STATES IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)

    FIGURE 23: CANADA IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)

    1. GEOGRAPHICAL ANALYSIS
      • NORTH AMERICA
        • UNITED STATES
          • CANADA
    1. MARKET BY PRESCRIPTION TYPE
      • PRESCRIBED
        • BRANDED
        • GENERIC
      • OVER THE COUNTER
    2. MARKET BY DRUG TYPE
      • LUBIPROSTONE
      • LINACLOTIDE
      • STIMULANT LAXATIVES
        • BISACODYL
        • SENNA
      • OSMOTIC LAXATIVES
        • LACTULOSE
        • POLYETHYLENE GLYCOL
        • OTHER DRUG TYPES

    To request a free sample copy of this report, please complete the form below :

    We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

      Choose License Type